Radnor, Pennsylvania--(Newsfile Corp. - March 11, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of RAPT Therapeutics, Inc. (NASDAQ: RAPT) ("RAPT").
On February 20, 2024, RAPT issued a press release revealing that the FDA "has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma" and that RAPT "expects to receive a formal clinical hold letter from the FDA." On this news, RAPT's stock price fell $5.08 per share, or 10.8%, to close at $41.97 per share on February 20, 2024.
If you are a RAPT investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser:https://www.ktmc.com/rapt-therapeutics-inc-investigation?utm_source=PR&utm_medium=link&utm_campaign=rapt&mktm=r
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/201227
